MidCity TMS

MidCity TMS in New York City offers Spravato esketamine nasal spray, an FDA-approved treatment for treatment-resistant depression and major depressive disorder with suicidal ideation. As of expanded FDA approval in January 2025, Spravato is also available as a standalone treatment for major depressive disorder. It works by targeting NMDA receptors to increase glutamate and promote synaptogenesis, offering relief often within hours to days.

Spravato is self-administered in a comfortable, private office setting, with patients monitored for two hours after each session. Treatment begins with two sessions per week for four weeks, followed by weekly sessions for another four weeks, then a tapered maintenance schedule.

Founded by Dr. Bryan Bruno, a psychiatrist with over 30 years of experience, MidCity TMS also offers TMS therapy, providing personalized, compassionate care for severe depression.